Subgroups
Bayer HealthCare
-
Wednesday - May 16, 2012
Not intended for U.S. and UK media - 48th Annual Meeting of the American Society of Clinical Oncology (ASCO):
Bayer to Present Data on Late-Stage Development Oncology Compounds at ASCO 2012
First data from Phase III trial for regorafenib in gastrointestinal tumors (GIST) presented as Late-Breaking Abstract in Oral Abstract Session / Updated survival results from Phase III trial for Alpharadin (radium-223 chloride) in castration-resistant prostate cancer (CRPC) presented as Late-Breaking Abstract in Oral Abstract Session » more
-
Thursday - May 10, 2012
Award from the Bayer Cares Foundation for innovative health projects
"Lebenstagebuch" wins Aspirin Social Award 2012
Berlin institution offers traumatized children of the Second World War unique writing therapy / 2nd place: Ärzte-Netzwerk Berlin (network of physicians in Berlin): Medical care for homeless people / 3rd place: REBOUND: Heidelberg drug prevention program for school students / Bayer Board of Management member Dr. Pott at award ceremony at Humboldt University in Berlin: "Innovative social initiatives with valuable contributions to health care" » more
-
Wednesday - May 9, 2012
Not intended for U.S. and UK media
Bayer’s Xarelto® (Rivaroxaban) Submitted to U.S. FDA to Reduce the Risk of Stent Thrombosis in Patients with Acute Coronary Syndrome » more
-
Wednesday - May 2, 2012
Not intended for U.S. and UK media:
Bayer’s Xarelto® (Rivaroxaban) Submitted to U.S. FDA for the Treatment of Venous Thromboembolism (VTE) and Long-Term Prevention of Recurrent VTE
Submissions for marketing authorization supported by the successful global EINSTEIN study program / Rivaroxaban is the first oral single-drug solution proven effective for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) » more
-
Friday - April 27, 2012
Annual Stockholders' Meeting 2012 » more
-
Thursday - April 26, 2012
1st quarter of 2012:
Encouraging start to the year for Bayer
Sales increased by 6.8 percent to a record EUR 10,056 million / Operating result (EBIT) climbed by 42.6 percent to EUR 1,637 million / EBITDA before special items rose by 9.4 percent to EUR 2,442 million / Strong start to the season at CropScience – increases at HealthCare – continuing margin pressure at MaterialScience / Net income advanced by 53.5 percent to EUR 1,050 million / 2012 guidance confirmed » more
-
Wednesday - April 25, 2012
Not intended for US or UK use - Aesthetic medicine:
Positive results from two European Phase III trials with ATX-101 demonstrate reduction of submental fat » more
-
Wednesday - April 25, 2012
Dr. Dirk Ehle appointed Head of Bayer HealthCare's Animal Health Division » more
-
Tuesday - April 24, 2012
Not intended for U.S. and UK media
Bayer expands targeted cancer therapy collaboration with Amgen » more
-
Tuesday - April 17, 2012
Not intended for U.S. and UK Media: Prevention of Venous Blood Clots after Elective Total Hip or Knee Replacement Surgery:
Real-World Experience Reaffirms Bayer’s Xarelto® (Rivaroxaban) as Safe and Effective in Protecting Patients Against Blood Clots
Outcomes from XAMOS study of more than 17,000 orthopaedic surgery patients provide further confirmation of clinical value of rivaroxaban / XAMOS reaffirms robust findings from RECORD – the world’s largest trial programme assessing oral anticoagulation in people requiring hip or knee replacement / Rivaroxaban is the world’s most prescribed new oral anticoagulant in the orthopaedic setting, with almost 2 million patients treated in this indication alone » more
-
Sunday - April 15, 2012
Not intended for U.S. and UK media - Molecular Imaging:
Bayer sells PET tracers to Piramal » more
-
Thursday - April 12, 2012
Diabetes Care:
Bayer HealthCare aims to improve diabetes management across borders
“Excellence across Borders” program initiated » more
-
Thursday - April 12, 2012
NOT INTENDED FOR UK MEDIA
Seresto® provides groundbreaking parasite protection in cats and dogs
New treatment from Bayer Animal Healthoffers cats and dogs up to eight months’ protection from ticks and fleas in a single treatment » more
-
Thursday - April 12, 2012
NOT INTENDED FOR UK MEDIA
New Seresto® keeps ticks and fleas at bay month after month
New collar from Bayer Animal Health offers dogs and cats an unparalleled protection period of up to eight months from ticks and fleas in a single treatment » more
-
Thursday - April 12, 2012
Not intended for U.S. and UK media
Bayer’s Xarelto® (Rivaroxaban) Submitted for EU Marketing Authorisation for the Treatment of Pulmonary Embolism (PE) and Prevention of Recurrent Deep Vein Thrombosis (DVT) and PE
Submission based on the successful outcome of EINSTEIN-PE study / Rivaroxaban offers the first oral single-drug solution for the initial treatment of PE and long-term prevention of DVT and PE » more
-
Wednesday - April 11, 2012
Not intended for U.S. and UK media
Bayer Updates U.S. Labels for Drospirenone-containing Combined Oral Contraceptives » more
-
Tuesday - April 3, 2012
Not intended for U.S. and U.K. Media
Phase III Trial of Regorafenib in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Meets Primary Endpoint of Improving Progression-Free Survival » more
-
Wednesday - March 28, 2012
Not intended for U.S. and UK Media - 103rd Annual Meeting American Association for Cancer Research:
Bayer to Present New Data on Oncology Pipeline
New Preclinical Data Evaluating Innovative Compounds will be presented / Growing Research and Development Portfolio » more
-
Tuesday - March 27, 2012
Bayer HealthCare and Beijing’s Tsinghua University extend innovative drug discovery partnership » more
-
Monday - March 26, 2012
Not intended for U.S. and UK Media - Treatment of Pulmonary Embolism (PE):
Bayer’s Xarelto® (Rivaroxaban) Proven Effective in Treating Patients with Pulmonary Embolism and in Preventing Recurrent Venous Blood Clots in Phase III EINSTEIN-PE Study
Rivaroxaban as effective as current standard of care in treatment of pulmonary embolism and secondary prevention of venous blood clots / Patients receiving rivaroxaban showed significantly reduced major bleedings compared to current standard of care / Rivaroxaban offers the first oral single-drug solution for the initial treatment and long-term prevention of pulmonary embolism / Study results presented as a Late-Breaker at the American College of Cardiology Annual Scientific Sessions and published in the New England Journal of Medicine » more
Copyright @ Bayer AG
Search
Publications
Newsletter
Events
Download Center - Selection
